Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7B9 | ISIN: US92941V3087 | Ticker-Symbol: 26JB
NASDAQ
20.05.24
21:58 Uhr
2,770 US-Dollar
-0,040
-1,42 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.VYNE Therapeutics Inc. - 10-Q, Quarterly Report1
09.05.Vyne Therapeutics Inc reports results for the quarter ended in January - Earnings Summary1
09.05.VYNE Therapeutics Inc. - 8-K, Current Report1
01.05.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting2
01.03.Vyne Therapeutics files for $250M mixed shelf1
01.03.VYNE Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
01.03.VYNE Therapeutics Inc. - 10-K, Annual Report1
29.02.Recap: VYNE Therapeutics Q4 Earnings2
29.02.VYNE Therapeutics Inc. - 8-K, Current Report1
29.02.VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update1782023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate...
► Artikel lesen
21.02.VYNE Therapeutics Inc.: VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference1
10.01.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo343VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
► Artikel lesen
03.01.VYNE Therapeutics Inc. - 8-K, Current Report1
13.12.23VYNE Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.12.23VYNE Therapeutics Inc. - 8-K, Current Report1
13.11.23VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update338Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...
► Artikel lesen
30.10.23VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo214Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was...
► Artikel lesen
14.08.23VYNE Therapeutics Inc.: VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update379Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1